Triglyceride-Glucose Index, LDL and Cardiovascular Outcomes in Chronic Stable Cardiovascular Disease: Results from the ONTARGET and TRANSCEND trials.

Cardiovascular Disease Mortality Myocardial Infarction Triglyceride Glucose Index

Journal

European journal of preventive cardiology
ISSN: 2047-4881
Titre abrégé: Eur J Prev Cardiol
Pays: England
ID NLM: 101564430

Informations de publication

Date de publication:
27 Oct 2023
Historique:
received: 19 09 2023
revised: 22 09 2023
accepted: 25 10 2023
medline: 27 10 2023
pubmed: 27 10 2023
entrez: 27 10 2023
Statut: aheadofprint

Résumé

The triglyceride-glucose (TyG) index has been proposed as an alternative to insulin resistance and as a predictor of cardiovascular outcomes. Little is known on its role in chronic stable cardiovascular disease and its predictive power at controlled low-density lipoprotein (LDL) levels. Our study population consisted of 29,960 participants in the ONTARGET and TRANSCEND trials that enrolled patients with known atherosclerotic disease. Triglycerides and glucose were measured at baseline. TyG was calculated as the logarithmized product of fasting triglycerides and glucose divided by 2. The primary endpoint of both trials was a composite of cardiovascular death, myocardial infarction, stroke or hospitalization for heart failure. The secondary endpoint was all-cause death and the components of the primary endpoint. Cox-proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) with extensive covariate adjustment for demographic, medical history and lifestyle factors. During a mean follow-up of 4.3 years, 4,895 primary endpoints and 3,571 all-cause deaths occurred. In fully adjusted models, individuals in the highest compared to the lowest quartile of the TyG index were at higher risk for the primary endpoint (HR 1.14; 95% CI 1.05-1.25) and for myocardial infarction (HR 1.30; 95% CI 1.11-1.53). A higher TyG index did not associate with the primary endpoint in individuals with LDL levels <100 mg/dl. A higher TyG index is associated with a modestly increased cardiovascular risk in chronic stable cardiovascular disease. This association is largely attenuated when LDL levels are controlled.Clinical Trial Registration Information - https://www.clinicaltrials.gov; Identifier: NCT00153101. The association of Triglyceride-glucose Index (TyG) with cardiovascular disease in chronic stable cardiovascular disease and its predictive power at controlled low-density lipoprotein (LDL) levels is unclear. Using a study population of 29,960 participants with chronic stable cardiovascular disease, we found that Higher TyG levels were associated with a modestly increased risk for incident cardiovascular events Low LDL levels largely attenuated the association of TyG with cardiovascular risk.

Sections du résumé

BACKGROUND BACKGROUND
The triglyceride-glucose (TyG) index has been proposed as an alternative to insulin resistance and as a predictor of cardiovascular outcomes. Little is known on its role in chronic stable cardiovascular disease and its predictive power at controlled low-density lipoprotein (LDL) levels.
METHODS METHODS
Our study population consisted of 29,960 participants in the ONTARGET and TRANSCEND trials that enrolled patients with known atherosclerotic disease. Triglycerides and glucose were measured at baseline. TyG was calculated as the logarithmized product of fasting triglycerides and glucose divided by 2. The primary endpoint of both trials was a composite of cardiovascular death, myocardial infarction, stroke or hospitalization for heart failure. The secondary endpoint was all-cause death and the components of the primary endpoint. Cox-proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) with extensive covariate adjustment for demographic, medical history and lifestyle factors.
RESULTS RESULTS
During a mean follow-up of 4.3 years, 4,895 primary endpoints and 3,571 all-cause deaths occurred. In fully adjusted models, individuals in the highest compared to the lowest quartile of the TyG index were at higher risk for the primary endpoint (HR 1.14; 95% CI 1.05-1.25) and for myocardial infarction (HR 1.30; 95% CI 1.11-1.53). A higher TyG index did not associate with the primary endpoint in individuals with LDL levels <100 mg/dl.
CONCLUSION CONCLUSIONS
A higher TyG index is associated with a modestly increased cardiovascular risk in chronic stable cardiovascular disease. This association is largely attenuated when LDL levels are controlled.Clinical Trial Registration Information - https://www.clinicaltrials.gov; Identifier: NCT00153101.
The association of Triglyceride-glucose Index (TyG) with cardiovascular disease in chronic stable cardiovascular disease and its predictive power at controlled low-density lipoprotein (LDL) levels is unclear. Using a study population of 29,960 participants with chronic stable cardiovascular disease, we found that Higher TyG levels were associated with a modestly increased risk for incident cardiovascular events Low LDL levels largely attenuated the association of TyG with cardiovascular risk.

Autres résumés

Type: plain-language-summary (eng)
The association of Triglyceride-glucose Index (TyG) with cardiovascular disease in chronic stable cardiovascular disease and its predictive power at controlled low-density lipoprotein (LDL) levels is unclear. Using a study population of 29,960 participants with chronic stable cardiovascular disease, we found that Higher TyG levels were associated with a modestly increased risk for incident cardiovascular events Low LDL levels largely attenuated the association of TyG with cardiovascular risk.

Identifiants

pubmed: 37890035
pii: 7331252
doi: 10.1093/eurjpc/zwad340
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT00153101']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Bernhard Haring (B)

Department of Medicine III, Saarland University, Homburg, Germany.
Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.

Helmut Schumacher (H)

Statistical Consultant, Ingelheim, Germany.

Giuseppe Mancia (G)

University of Milano-Bicocca, Instituto Clinico Universitario Policlinico di Monza, Piazza dell'Ateneo Nuovo, 1, Milano, Italy.

Koon K Teo (KK)

Population Health Research Institute, McMaster University, and Hamilton Health Sciences, Hamilton, Ontario, Canada.

Eva M Lonn (EM)

Population Health Research Institute, McMaster University, and Hamilton Health Sciences, Hamilton, Ontario, Canada.

Felix Mahfoud (F)

Department of Medicine III, Saarland University, Homburg, Germany.

Roland Schmieder (R)

Department of Nephrology and Hypertension, University Hospital, Friedrich-Alexander University, Erlangen, Nuremberg, Germany.

Johannes F E Mann (JFE)

KfH Kidney Centre, München, Germany and Department of Nephrology and Hypertension, University Hospital, Friedrich-Alexander University, Erlangen, Germany.

Karen Sliwa (K)

Faculty of Health Sciences, Hatter Institute for Cardiovascular Research in Africa & IIDMM, University of Cape Town, Cape Town, South Africa.

Salim Yusuf (S)

Population Health Research Institute, McMaster University, and Hamilton Health Sciences, Hamilton, Ontario, Canada.

Michael Böhm (M)

Department of Medicine III, Saarland University, Homburg, Germany.

Classifications MeSH